戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 in systolic and diastolic diameter (akin to 'restrictive cardiomyopathy').
2 fferentiating constrictive pericarditis from restrictive cardiomyopathy.
3 nts with known constrictive pericarditis and restrictive cardiomyopathy.
4 ing comparable to that observed during human restrictive cardiomyopathy.
5  the 58 children with mixed hypertrophic and restrictive cardiomyopathy.
6 sm or with mixed hypertrophic and dilated or restrictive cardiomyopathy.
7 sease should be ongoing in all patients with restrictive cardiomyopathy.
8 TnI) mutation R145W has been associated with restrictive cardiomyopathy.
9 or which mutations have been associated with restrictive cardiomyopathy.
10 icit and possibly reduced cardiac output and restrictive cardiomyopathy.
11  of RNAi therapeutics directed towards human restrictive cardiomyopathy.
12 ic pattern of impaired diastolic filling and restrictive cardiomyopathy.
13 differentiate constrictive pericarditis from restrictive cardiomyopathy.
14 cities are markedly reduced in patients with restrictive cardiomyopathy.
15 fferentiating constrictive pericarditis from restrictive cardiomyopathy.
16 usative for dilated (DCM), hypertrophic, and restrictive cardiomyopathy.
17 rms of HF include hypertrophic, dilated, and restrictive cardiomyopathy.
18 tations result in amyloid polyneuropathy and restrictive cardiomyopathy.
19 y diagnosed with dilated, arrhythmogenic, or restrictive cardiomyopathies.
20 nts are implicated in DCM, hypertrophic, and restrictive cardiomyopathies.
21  dilated cardiomyopathy (14.8%), followed by restrictive cardiomyopathy (13.5%), whereas other forms
22 udden cardiac death is common in humans with restrictive cardiomyopathies and long QT syndromes.
23 ilial amyloidosis (11), hemochromatosis (1), restrictive cardiomyopathy and cardiac cirrhosis (1), pr
24 yloid deposition leads to an infiltrative or restrictive cardiomyopathy and is the major contributor
25 nction between constrictive pericarditis and restrictive cardiomyopathy and may prove to be valuable
26 eak early diastolic velocity is blunted with restrictive cardiomyopathy and preserved with constricti
27 r hypertrophic cardiomyopathy (HCM), 12% for restrictive cardiomyopathy, and 23% for left ventricular
28 s, including left ventricular noncompaction, restrictive cardiomyopathy, and arrhythmogenic cardiomyo
29 tions within this region are associated with restrictive cardiomyopathy, and C-terminal deletion of c
30                                          The restrictive cardiomyopathies are a heterogenous group of
31                      Pediatric patients with restrictive cardiomyopathy are at risk for acute high-gr
32  although other forms of cardiomyopathy (ie, restrictive cardiomyopathy, arrhythmogenic right ventric
33 on, force transmission disease; hypertrophic-restrictive cardiomyopathies as sarcomeric, force genera
34                                    Pediatric restrictive cardiomyopathy carries a poor prognosis seco
35 rwent cardiac transplantation as a result of restrictive cardiomyopathy caused by a heterozygous R406
36 myloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy caused by extracellular depos
37 trospective study of pediatric patients with restrictive cardiomyopathy diagnosed between April 1994
38 relaxation is a hallmark of hypertrophic and restrictive cardiomyopathies (HCM and RCM).
39 man sarcomeric mutation in MYL2 causative of restrictive cardiomyopathy in a mouse model.
40 t proline to leucine (P838L) caused dominant restrictive cardiomyopathy in a pediatric patient.
41                                   Idiopathic restrictive cardiomyopathy is a poorly recognized entity
42                                              Restrictive cardiomyopathy is a rare heart disease assoc
43 11 requiring ventilation) and 12 (75%) had a restrictive cardiomyopathy, leading to heart failure and
44 al echocardiographic criteria for idiopathic restrictive cardiomyopathy, mainly dilated atria with no
45     Consistent with the pathophysiology, the restrictive cardiomyopathy mutation, troponin I R192H, a
46 st genetic testing diagnostic yields were in restrictive cardiomyopathy (n=16, 80%) and hypertrophic
47                  Eleven (68.8%) patients had restrictive cardiomyopathy on initial assessment.
48 nt number of suspected HFpEF patients have a restrictive cardiomyopathy or chronic pericardial diseas
49                                   Idiopathic restrictive cardiomyopathy or nondilated, nonhypertrophi
50 ically proven CP and 10 patients without CP (restrictive cardiomyopathy or severe tricuspid regurgita
51 mall children with congenital heart disease, restrictive cardiomyopathy, or hypertrophic cardiomyopat
52 ological factors responsible for causing the restrictive cardiomyopathy phenotype in some of the gene
53 LNC variants among patients with dilated and restrictive cardiomyopathies, pointed to this gene as an
54           The differential diagnosis between restrictive cardiomyopathy (RCM) and constrictive perica
55                                              Restrictive cardiomyopathy (RCM) has been associated wit
56 ation of constrictive pericarditis (CP) from restrictive cardiomyopathy (RCM) is a complex and often
57                                    Inherited restrictive cardiomyopathy (RCM) is a debilitating disea
58                                              Restrictive cardiomyopathy (RCM) is a rare cardiomyopath
59                                              Restrictive cardiomyopathy (RCM) is a rare disorder char
60                                              Restrictive cardiomyopathy (RCM) is an uncommon heart mu
61                                              Restrictive cardiomyopathy (RCM) is characterized by non
62                                              Restrictive cardiomyopathy (RCM) is rare in children, an
63 s with hypertrophic cardiomyopathy (HCM) and restrictive cardiomyopathy (RCM) using a targeted panel
64 atural killer (NK) cell deficiency (NKD) and restrictive cardiomyopathy (RCM) with hypoplasia of the
65 use hypertrophic (HCM), dilated (DCM) and/or restrictive cardiomyopathy (RCM), but disease-causing me
66 anics of constrictive pericarditis (CP) with restrictive cardiomyopathy (RCM), or healthy controls; t
67 n I (cTnI) R145W mutation is associated with restrictive cardiomyopathy (RCM).
68 g chronic constrictive pericarditis (CP) and restrictive cardiomyopathy (RCM).
69 thy (HCM), dilated cardiomyopathy (DCM), and restrictive cardiomyopathy (RCM).
70 ases like constrictive pericarditis (CP) and restrictive cardiomyopathy (RCM).
71 d cardiomyopathy (DCM, n=19 921), nonamyloid restrictive cardiomyopathy (RCM, n=248), or ACM (n=46) b
72 tcomes of candidates with rare causes of HF (restrictive cardiomyopathy [RCM], hypertrophic cardiomyo
73 rentiate constrictive pericarditis (CP) from restrictive cardiomyopathy (RCMP).
74 on that is seen in patients suffering from a restrictive cardiomyopathy that is associated with the c
75                                              Restrictive cardiomyopathy was suggested by reduced aver
76    Heart failure associated with unexplained restrictive cardiomyopathy was the most common clinical
77 5W, A171T, K178E, and R192H) associated with restrictive cardiomyopathy were distinguishable from hyp
78 s with constrictive pericarditis and 44 with restrictive cardiomyopathy were used for developing an a
79 first described >75 years ago, is a cause of restrictive cardiomyopathy with an unclear aetiopathogen
80 by massive fibrosis resulting in early-onset restrictive cardiomyopathy with increased mortality as o
81 rther activation of PKCalpha caused a lethal restrictive cardiomyopathy with marked interstitial fibr